Compugen Ltd. (NASDAQ: CGEN) announced it would be giving a presentation at the Keystone Symposium on existing the immune tumor microenvironment through single-cell spatial transcriptions. This event will occur between March 20 and 24 in BC, Canada. Compugen’s presentation will be on March 21.
Compugen is a company that focuses on developing and discovering therapies. It uses its platform to find new targets for drugs. It also works on finding biological pathways to create cancer immunotherapies.
COM701 and COM902 are Compugen’s top drug candidates
The company has two candidates to treat solid tumors. These candidates are COM701 and COM902. COM701 is an anti-PVRIG antibody for solid tumors. The drug could be used as a single therapy or double and triple-drug combination.
COM902, on the other hand, is a monoclonal antibody that targets TIGIT. Unlike COM701, it treats both hematological and solid tumors. The company is testing the drug in a Phase II trial as a single agent. It is also testing its efficacy when used with COM702. Moreover, the company is testing the drug in patients with advanced tumors.
Another drug the company is developing is Bapotulimab. This therapeutic antibody targets ILDR2. The company is conducting Phase I clinical trials of the drug in patients with solid tumors.
Compugen is also testing AZD2936, an anti TIGIT/PD-1 antibody, in a Phase 1/2 study. The company hopes to use the compound on people with metastatic or advanced non-small cellular cancer thus is testing them on this group of patients.
Compugen’s partnerships
The company is currently partnering with Bayer Pharma to commercialize, develop and research antibody-based treatments against its Bristol-Meyers Squibb. The partnership intends to test the tolerability and safety of Bristol-Myers Squibb in combination with COM701 in patients with solid tumors.
Compugen is also collaborating with the John Hopkins School of Medicine to investigate myeloid and T cell targets. Furthermore, the company established a licensing agreement with AstraZeneca to develop multi and bi-specific antibody products that are immuno-oncology related.
Compugen has operations in Europe, the U.S, and Israel, where it commercializes, develops, and researchers product candidates. The company is also working on immuno-oncology projects focused on myeloid targets. The company has its headquarters in Holon, Israel.
